Cocrystal Pharma rises as FDA fast-tracks oral norovirus drug

Cocrystal Pharma

02/04/2026 13:25

** Shares of drug developer Cocrystal Pharma COCP.O rise 9% to $1.10 premarket

** Co says FDA grants fast-track status to its experimental oral drug CDI-988 for norovirus, a highly contagious stomach virus that causes vomiting and diarrhea; no approved treatments exist

** CDI-988 is being tested in an early-stage study in up to 40 healthy adults to reduce norovirus symptoms and assess safety and how the drug moves through the body, co says

** Says norovirus hits immunocompromised patients hardest, often causing long-term infections; CDI-988 is not yet approved

** Fast-track status aims to speed development and review for drugs addressing serious diseases with unmet medical needs

** As of last close, stock up ~4% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))